A phase II trial of RAD001 and bicalutamide for androgen independent prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Bicalutamide (Primary) ; Everolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 06 Nov 2017 Status changed to completed.
- 10 Jun 2017 Biomarkers information updated
- 05 Feb 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.